We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

24 hedge funds and large institutions have $5.17M invested in CASI Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 24 → 24 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

1.47% less ownership

Funds ownership: 16.08% → 14.61% (-1.5%)

17% less capital invested

Capital invested by funds: $6.26M → $5.17M (-$1.09M)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
24
Holders Change
–
Holders Change %
0%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$108K
2
Prudential Financial
Prudential Financial
New Jersey
+$35.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$33.5K
4
WSCM
Wellington Shields Capital Management
New York
+$16.1K
5
UBS Group
UBS Group
Switzerland
+$9.94K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$378K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$157K
3
B
Bailard
California
-$90K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$54.3K
5
RC
RBF Capital
California
-$46K

CASI Hedge Fund Activity: Q3 2022 in Review

24 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2022, worth a combined $5.17M — down 17% from $6.26M a quarter earlier.

Fund positioning in CASI was balanced in Q3 2022: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $108K. The largest seller was Ikarian Capital, exiting entirely with an estimated $378K sold.

  • 24 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $5.17M of CASI Pharmaceuticals stock for Q3 2022, down 17% quarter-over-quarter.
  • 6 funds opened new CASI Pharmaceuticals positions in Q3 2022 and 6 closed out, a net change of 0 holders.
  • The largest CASI Pharmaceuticals buyer in Q3 2022 was Susquehanna International Group, an estimated $108K added.
  • The largest CASI Pharmaceuticals seller in Q3 2022 was Ikarian Capital, an estimated $378K sold.

Based on aggregated 13F filings for Q3 2022.